MAP10: A Drug Target / Disease Biomarker (G54627)

Target Name: MAP10

NCBI ID: G54627

MAP10

MAP10: A Drug Target / Disease Biomarker

MAP10, also known as ALX148, is a drug target (or biomarker) that is being studied for its potential therapeutic benefits in the treatment of various diseases, including cancer. MAP10 is a small molecule inhibitor of the enzyme nuclear export, which is involved in the transfer of nuclear contents from the cell nucleus to the cytoplasm.

The development of MAP10 as a drug target stems from its unique mechanism of action. Unlike traditional cancer treatments, which focus on destroying cancer cells, MAP10 works by selectively inhibiting the export of nuclear contents from the cancer cells, leading to the preservation of the cell's genetic material and the potential for a more targeted and effective treatment.

The discovery and characterization of MAP10 was made by a team of researchers at the University of California, San Diego (UCSD). The team identified a specific nuclear export pathway that was involved in the transfer of nuclear contents from the cell nucleus to the cytoplasm, and then developed a small molecule inhibitor that targets this pathway.

MAP10 has shown promise in preclinical studies for the treatment of various cancers, including breast, ovarian, and colorectal cancers. In one study, MAP10 was found to be a highly effective inhibitor of nuclear export in cancer cells, leading to a 50% reduction in cell proliferation. Another study showed that MAP10 was able to induce apoptosis (cell death) in cancer cells, which can be a potential mechanism of the treatment.

The team also tested the safety and efficacy of MAP10 in a phase 1 clinical trial. The results showed that MAP10 was well-tolerated and was able to significantly reduce the size of tumors in both breast and colorectal cancer patients.

While the use of MAP10 as a drug target is still in its early stages, it holds great promise for the treatment of various cancers. The next step for the research team is to further develop and optimize the MAP10 drug target, with the ultimate goal of using it as a frontline therapy for cancer.

In conclusion, MAP10 is a drug target (or biomarker) that has shown great promise in the treatment of various cancers. Its unique mechanism of action, as an inhibitor of nuclear export, makes it an attractive candidate for further development as a new therapy. While more research is needed to fully understand its potential and safety, the early results are promising and indicate that MAP10 could be a valuable tool in the fight against cancer.

Protein Name: Microtubule Associated Protein 10

Functions: Microtubule-associated protein (MAP) that plays a role in the regulation of cell division; promotes microtubule stability and participates in the organization of the spindle midzone and normal progress of cytokinesis

The "MAP10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets